Glenmark Pharmaceuticals is currently trading at Rs. 2076.25, up by 37.65 points or 1.85% from its previous closing of Rs. 2038.60 on the BSE.

The scrip opened at Rs. 2038.85 and has touched a high and low of Rs. 2082.00 and Rs. 2038.60 respectively. So far 15270 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2286.15 on 11-Jul-2025 and a 52 week low of Rs. 1274.70 on 28-Feb-2025.

Last one week high and low of the scrip stood at Rs. 2082.00 and Rs. 1921.55 respectively. The current market cap of the company is Rs. 58457.90 crore.

The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.38% and 13.97% respectively.

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. Glenmark’s Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) of BPI Labs, LLC. 

According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market achieved annual sales of around $67.6 million. Glenmark’s Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is only approved for the indication(s) listed in Glenmark’s approved label.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.